Case series of low dose rituximab for membranous nephropathy; a single centre experience
Introduction: Rituximab is the recent treatment of choice for primary membranous nephropathy However, dose of rituximab mentioned in literature is high and not economical in middle income countries. Low dose rituximab based on CD 19 cell count can be tried as an alternative for high dose rituximab f...
Shranjeno v:
Main Authors: | , , |
---|---|
Format: | Knjiga |
Izdano: |
Society of Diabetic Nephropathy Prevention,
2023-06-01T00:00:00Z.
|
Teme: | |
Online dostop: | Connect to this object online. |
Oznake: |
Označite
Brez oznak, prvi označite!
|
Internet
Connect to this object online.3rd Floor Main Library
Signatura: |
A1234.567 |
---|---|
Kopija 1 | Prosto |